Zentalis Pharmaceuticals (ZNTL) Operating Leases (2020 - 2026)

Zentalis Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $38.7 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 8.32% year-over-year to $38.7 million in Q1 2026; TTM through Mar 2026 was $38.7 million, a 8.32% decrease from a year earlier, with the FY2025 full-year figure at $35.7 million, down 9.79% from the prior year.
• Operating Leases advanced to $38.7 million in Q1 2026 per ZNTL's latest filing, from $35.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $47.0 million in Q1 2023 and bottomed at $35.7 million in Q4 2025.
• The 5-year median for Operating Leases is $42.7 million (2023), against an average of $41.9 million.
• Across the five-year window, Operating Leases climbed 1.59% in 2022 and fell 9.79% in 2025, its largest moves.
• Year by year, Operating Leases stood at $45.2 million in 2022, then fell by 4.46% to $43.2 million in 2023, then decreased by 8.28% to $39.6 million in 2024, then fell by 9.79% to $35.7 million in 2025, then gained by 8.25% to $38.7 million in 2026.
• Per Business Quant, the three latest ZNTL Operating Leases figures stand at $38.7 million (Q1 2026), $35.7 million (Q4 2025), and $36.7 million (Q3 2025).